Bright Minds Biosciences (DRUG) Stock News
$DRUG · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Bright Minds Biosciences (DRUG) in the past 30 days, 1 of it high impact. BORSA’s news read on DRUG is bearish at 24/100, based on 1 company event over the past 7 days. Bright Minds Biosciences’ next earnings report is scheduled for Tuesday, Dec 22.
The wire on $DRUG
newest first · updated · direct subject stories onlyThe FDA notified Bright Minds Biosciences that its IND for BMB-101 in developmental and epileptic encephalopathies has been placed on a partial clinical hold. The hold covers only the planned Phase 2 trial in the US. The FDA cited identified toxicity in mice and inadequate pharmacokinetic and juvenile toxicity data to support pediatric enrollment. The company believes the mouse findings were incidental and not drug-related. Bright Minds is awaiting the full hold letter and intends to work with the FDA to address the issues.
bearish 20 · impact 70The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Bright Minds Biosciences (DRUG) stock: common questions
What is the latest Bright Minds Biosciences stock news?
The highest-impact DRUG story BORSA published in the past 30 days:
·